NewAmsterdam Pharma's Upcoming Medical Engagements and Updates
NewAmsterdam Pharma's Upcoming Medical Engagements
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a prominent player in the late-stage biopharmaceutical sector, has exciting developments on the horizon. With a focus on advancing patient care for those grappling with cardiovascular disease, the company is gearing up for its presentations at significant medical meetings and investor conferences.
AHA Scientific Sessions 2025 Presentation Details
One of the key highlights will be NewAmsterdam's presentation of safety and efficacy data from its pivotal Phase 3 trials: BROOKLYN, BROADWAY, and TANDEM. These trials are crucial in exploring the effectiveness of oral, non-statin medicines for individuals with heightened low-density lipoprotein cholesterol.
AHA Presentation Titles
The first noteworthy presentation is titled "Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles." This oral presentation is scheduled for November 9, 2025, at 10:15 am CT, featuring insights from lead presenter John Kastelein.
Following this, there will be a digital poster presentation on "Obicetrapib in Combination with Ezetimibe on Top of Atorvastatin Regresses Atherosclerotic Plaque Lesions in APOE*3-Leiden CETP Mice." This innovative presentation is set for November 10, 2025, at 10:59 am CT, showcasing the work of Jose Inia.
Upcoming Investor Conferences
NewAmsterdam Pharma also has a robust schedule for investor interactions, starting with the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, at 10:30 am ET in Boston. Key representatives will include their Chief Executive Officer Michael Davidson, M.D., and Chief Financial Officer Ian Somaiya.
Following that, on November 12, 2025, at 8:00 am ET, they will participate in the Stifel Healthcare Conference, providing another platform for investors to engage with company leadership.
Lastly, on November 19, 2025, at 5:00 pm GMT, they will feature at the Jefferies London Healthcare Conference, where Ian Somaiya will be joined by John Kastelein, M.D., Ph.D., the Founder and Chief Scientific Officer. These platforms will not only provide valuable insights into the company's ongoing research but also allow for direct engagement with the leadership team.
Accessing Live Webcasts
Live webcasts of these investor discussions will be accessible via the investor relations section of NewAmsterdam Pharma's website. These discussions will be archived for future viewing, enabling stakeholders and interested parties to gain insights into the company's strategies and research outcomes.
About NewAmsterdam
NewAmsterdam Pharma is dedicated to enhancing patient care in metabolic diseases where existing therapies fall short. Their investigation of obicetrapib aims to offer a well-tolerated and effective LDL-lowering treatment for patients at risk of cardiovascular complications. In their ongoing Phase 3 trials, they explore this treatment's efficacy in combination with existing medications for holistic cardiovascular care.
Company Contact Information
Contact Matthew Philippe for corporate inquiries at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.
Media and Investor Contacts
For media inquiries, contact Real Chemistry on behalf of NewAmsterdam, Christian Edgington at 1-513-310-6410 or via email at cedgington@realchemistry.com.
For investor communications, reach out to Austin Murtagh from Precision AQ at 1-212-698-8696 or at austin.murtagh@precisionaq.com.
Frequently Asked Questions
What is NewAmsterdam Pharma known for?
NewAmsterdam Pharma specializes in developing innovative therapies aimed at addressing cardiovascular disease, focusing on LDL-lowering treatments.
When are NewAmsterdam's major upcoming presentations?
The key presentations at the AHA Scientific Sessions will occur on November 9 and 10, 2025.
How can I access the investor conferences?
Live and archived webcasts of the investor discussions will be available on NewAmsterdam's investor relations website.
Who will be presenting at the conferences?
Key executives including CEO Michael Davidson and CFO Ian Somaiya will represent the company at the various conferences.
What are the main trials being discussed?
The presentations will cover findings from the BROOKLYN, BROADWAY, and TANDEM trials focusing on obicetrapib's efficacy.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.